The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer
Top Cited Papers
- 29 August 2008
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (18) , 5522-5532
- https://doi.org/10.1021/jm800295d
Abstract
Phosphatidylinositol-3-kinase (PI3K) is an important target in cancer due to the deregulation of the PI3K/Akt signaling pathway in a wide variety of tumors. A series of thieno[3,2-d]pyrimidine derivatives were prepared and evaluated as inhibitors of PI3 kinase p110α. The synthesis, biological activity, and further profiling of these compounds are described. This work resulted in the discovery of 17, GDC-0941, which is a potent, selective, orally bioavailable inhibitor of PI3K and is currently being evaluated in human clinical trials for the treatment of cancer.Keywords
This publication has 26 references indexed in Scilit:
- A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast CancerCancer Cell, 2007
- Exploiting the PI3K/AKT Pathway for Cancer Drug DiscoveryNature Reviews Drug Discovery, 2005
- Mutations in a signalling pathwayNature, 2005
- High Frequency of Mutations of the PIK3CA Gene in Human CancersScience, 2004
- PTEN: from pathology to biologyTrends in Cell Biology, 2003
- The phosphatidylinositol 3-Kinase–AKT pathway in human cancerNature Reviews Cancer, 2002
- The Phosphoinositide 3-Kinase PathwayScience, 2002
- Synthesis and Function of 3-Phosphorylated Inositol LipidsAnnual Review of Biochemistry, 2001
- PIK3CA is implicated as an oncogene in ovarian cancerNature Genetics, 1999
- PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate CancerScience, 1997